Find a Doctor

PT
Areas of Expertise

Przemyslaw W. Twardowski

Providence Saint Johns Medical Foundation
Oncology, Internal Medicine
Male

Bio

Przemyslaw Twardowski is an Oncologist and an Internal Medicine specialist in Santa Monica, California. He has been an author on 59 peer reviewed articles and participated in 2 clinical trials in the past 15 years. He is licensed to treat patients in CA.

Areas of Expertise

Contact

2121 Santa Monica Blvd
Santa Monica, CA 90404, US

310-582-7137

Latest Research

Latest Advance
Study
  • Condition: Prostate Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Olaparib
  • Number of Patients: 387
  • Published —
In this study, researchers evaluated the outcomes of using olaparib for the treatment of metastatic castration-resistant prostate cancer.
Latest Advance
Study
  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Olaparib
  • Number of Patients: 0
  • Published —
The study researched the safety and effectiveness of Olaparib in patients with metastatic castration-resistant prostate cancer.
Latest Advance
Study
  • Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Journal: Cancer treatment and research communications
  • Treatment Used: Sipuleucel-T Immunotherapy Preceded by Sensitizing Radiation Therapy (RT) and Sipuleucel-T Alone
  • Number of Patients: 51
  • Published —
This study evaluated the safety and effectiveness of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer (mCRPC).
Latest Advance
Study
  • Condition: Metastatic Urothelial Cancer
  • Journal: European urology
  • Treatment Used: Gemcitabine, Cisplatin, plus Ipilimumab
  • Number of Patients: 36
  • Published —
This study determined the safety, effectiveness, and immunomodulatory effects of gemcitabine and cisplatin (GC) plus ipilimumab, and explored the impact of somatic DNA damage response gene alterations on antitumor activity in patients with metastatic urothelial cancer.

Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Other, Drug
  • Participants: 132
  • Start Date: January 15, 2021
A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 86
  • Start Date: April 1, 2019
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

All Publications
View All

Publication
Conference
  • Sponsor: Society for ImmunoTherapy of Cancer (SITC)
  • Event Name: Society for ImmunoTherapy of Cancer Annual Scientific Meeting 2020
  • Published —
EMERGING SAFETY AND ACTIVITY DATA FROM GEN- 009–101: A PHASE 1/2A TRIAL OF GEN-009, A NEOANTIGEN VACCINE IN COMBINATION WITH PD-1 CHECK-POINT INHIBITORS (CPI) IN ADVANCED SOLID TUMORS
Publication
Study
  • Journal: The Journal of urology
  • Published —
Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data.

Contact

2121 Santa Monica Blvd
Santa Monica, CA 90404, US

310-582-7137

Affiliations

  • Providence Saint John's Health Center

Credentials

  • Graduate InstitutionUniversity Of Missouri, Kansas City, School Of Medicine
  • Licenses
    Internal Medicine in CA
  • Board Certifications
    Medical Oncology

Insurance

Contact them to find out if they accept your insurance plan.